ResMed reported an earnings per share (EPS) of $2.55, beating the estimated $2.51 and marking a significant year-over-year improvement.The company's revenue reached $1.34 billion, exceeding estimates and showcasing a 9.1% increase from the previous year.Operational metrics such as gross margin and income from operations saw notable improvements, indicating efficient cost management and operational excellence.ResMed Inc. (NYSE:RMD) is a prominent player in the medical products industry, focusing on innovativ ...

Stryker (SYK) came out with quarterly earnings of $3.19 per share, beating the Zacks Consensus Estimate of $3.14 per share. This compares to earnings of $2.87 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +1.59%. A quarter ago, it was expected that this medical device maker would post earnings of $3.06 per share when it actually produced earnings of $3.13, delivering a surprise of +2.29%.Over the last four quarters, the comp ...

ResMed (RMD) came out with quarterly earnings of $2.55 per share, beating the Zacks Consensus Estimate of $2.49 per share. This compares to earnings of $2.2 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +2.41%. A quarter ago, it was expected that this maker of medical products for respiratory disorders would post earnings of $2.46 per share when it actually produced earnings of $2.55, delivering a surprise of +3.66%.Over the ...

Capricor Therapeutics (CAPR) shares soared 12% in the last trading session to close at $6.92. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 14.3% loss over the past four weeks.The sharp rise in CAPR shares can be attributed to the company’s recent regulatory progress and growing optimism around upcoming clinical milestones. Management’s prior update confirming FDA alignment on trial endpoints has strengthened expectations for a ...

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.26 per share, missing the Zacks Consensus Estimate of $2.3 per share. This compares to earnings of $2.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -1.74%. A quarter ago, it was expected that this maker of instruments used in biomedical research would post earnings of $1.93 per share when it actually produced earnings of $2.61, delivering a surprise of +35. ...

AtriCure (ATRC) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +90.91%. A quarter ago, it was expected that this medical device maker would post a loss of $0.15 per share when it actually produced a loss of $0.02, delivering a surprise of +86.67%.Over the last four quarters, the company ha ...

Verano Holdings Corp. (VRNOF) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -140.00%. A quarter ago, it was expected that this company would post a loss of $0.05 per share when it actually produced a loss of $0.05, delivering no surprise.Over the last four quarters, the company has surpas ...

GE HealthCare Technologies (GEHC) came out with quarterly earnings of $1.07 per share, beating the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $1.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +1.90%. A quarter ago, it was expected that this medical technology company would post earnings of $0.91 per share when it actually produced earnings of $1.06, delivering a surprise of +16.48%.Over the l ...

公司人事变动 - 公司于2025年10月23日召开董事会审议通过聘任李玉洁女士为证券事务代表的议案 [1] - 新任证券事务代表将协助董事会秘书履行职责 任期自董事会审议通过之日起至第四届董事会任期届满之日止 [1] 公司业务构成 - 2025年1至6月份公司营业收入构成为通信行业占比48.67% 车联网占比46.44% 医疗产品行业占比4.89% [1] - 通信和车联网业务是公司核心收入来源 两者合计占比超过95% [1] 公司市场表现 - 公司当前收盘价为42.41元 截至发稿市值为57亿元 [1]

财务业绩 - 公司报告季度每股收益为盈亏平衡，超出市场预期的每股亏损0.03美元，去年同期为每股亏损0.04美元 [1] - 本季度盈利超出预期+100%，上一季度实际每股收益0.02美元，超出预期+166.67% [1] - 在过去四个季度中，公司有两次超出每股收益预期 [2] 收入表现 - 季度收入为2.095亿美元，超出市场预期1.29%，去年同期收入为2.0004亿美元 [2] - 在过去四个季度中，公司仅有一次超出收入预期 [2] 股价表现与市场比较 - 公司股价年初至今上涨约29.3%，同期标普500指数上涨14.8% [3] - 公司所属的Zacks医疗产品行业在250多个行业中排名前26% [8] 未来展望与预期 - 当前市场对下一季度的共识预期为每股亏损0.03美元，收入2.159亿美元 [7] - 当前财年共识预期为每股亏损0.11美元，收入8.7728亿美元 [7] - 盈利预期修正趋势在财报发布前表现不一 [6] 同业公司比较 - 同业公司OraSure Technologies预计在即将发布的报告中公布季度每股亏损0.16美元，同比变化-1500% [9] - 该公司季度每股收益预期在过去30天内下调22.6%，预期收入2914万美元，同比下降27% [9]